Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.
first published: May 8, 2013 11:14 am
A collection of the most-viewed Moneycontrol videos.
Point-to-Point vs Rolling Returns for Mutual Funds: Full Breakdown
From Hesitant Heir to Undisputed Leader: Sanjiv Bajaj's Leadership Story
Nifty Fails To Defend 26,000 Amid Sluggish Start To Final Week Of 2025| Closing Bell Live
Nifty Aims To Defend 26,000 Amid Thin Volumes, Record-Low VIX| Opening Bell Live
